Aspen Group, Inc. ASPU
0.21 USD 0.00 (+0.00%)
As ofNov 18, 2026, 11:47 AM EST
0.2116 Day range 0.2116
0.0801 52-week range 0.41
- YTD
- +25.80%
- 1 year
- +62.77%
News
reuters.com Aspen Pharmacare wins approval for generic semaglutide in Brazil, South Africa Aspen Pharmacare wins approval for generic semaglutide in Brazil, South Africa
globenewswire.com Rocky Mountain Chocolate Factory Announces Houston Airport Store Opening and Aspen Lease Signing Houston store opening expands airport presence while Aspen lease adds an iconic Colorado destination to RMCF's development pipeline Houston store opening expands airport presence while Aspen lease…
marketbeat.com Aspen Aerogels Q3 Earnings Call Highlights Aspen Aerogels NYSE: ASPN reported third-quarter revenue and adjusted earnings above its guidance, helped by energy industrial project deliveries, higher sales to General Motors and growing demand…
globenewswire.com Aspen Aerogels Appoints Stacy Nieuwoudt to Board of Directors NORTHBOROUGH, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the "Company"), a technology leader in sustainability and electrification solutions, today…
globenewswire.com Aspen Aerogels, Inc. Reports Third Quarter 2026 Financial Results and Recent Business Highlights Q3 2026 revenue of $85 million, up 71% quarter-over-quarter and above the high end of outlook Q3 2026 net loss of $10 million; Adjusted EBITDA of $20 million, above the high end of outlook Received…
globenewswire.com Aspen Neuroscience Announces Pricing of Initial Public Offering SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage regenerative medicine biotechnology company developing autologous cell therapies for Parkinson's…
seekingalpha.com Aspen Neuroscience Pursues IPO On Promising Parkinson's Disease Treatment Candidates Aspen Neuroscience is pursuing a $150 million IPO to fund Parkinson's Disease stem cell therapies. ASPE's lead candidate, sasineprocel, shows promising mid-stage efficacy but has procedure-related…
globenewswire.com Aspen Aerogels, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call NORTHBOROUGH, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the "Company") today announced that Don Young, President & Chief Executive Officer, and Grant…
globenewswire.com Aspen Group Delivers Net Income of $0.7 Million for First Quarter Fiscal Year 2027 Generated operating cash flow of $0.7 million in the first quarter, enabling the resumption of marketing spend Revenue held steady at $10.3 million for the third consecutive quarter; United States…
globenewswire.com Aspen Group Announces Leadership Transition at United States University and Aspen University PHOENIX, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (“AGI”) (OTCQB: ASPU), an education technology holding company and the parent company of Aspen University (AU) and United States…
businesswire.com AM Best Removes From Under Review With Positive Implications and Upgrades Credit Ratings of Aspen Insurance Holdings Limited and its Rated Subsidiaries OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has removed from under review with positive implications and upgraded the Financial Strength Rating (FSR) to A+ (Superior) from A (Excellent) and…
reuters.com Aspen sees Mounjaro Africa sales above $124 million in 2027 Aspen Pharmacare expects African sales of Eli Lilly's blockbuster weight-loss and diabetes drug Mounjaro to exceed 2 billion rand ($124 million) in its current financial year, buoyed by surging…
globenewswire.com Aspen Group Reports Fourth Quarter and Fiscal Year 2026 Results United States University revenue increased 5% during Fiscal 2026, driven by solid organic lead generation Generated operating cash flow of $1.0 million in the fourth quarter, up from $0.6 million,…
seekingalpha.com Aspen Aerogels: Green Shoots Fail To Truly Impress Investors Aspen Aerogels delivered sequential revenue and EBITDA improvement, with Q2 revenues topping guidance and Q3 outlook signaling further recovery. Thermal Barrier sales rebounded sequentially,…
seekingalpha.com Aspen Aerogels Reminds Us Materials Science Can Be Cool, Especially If EVs Are Hot Consider the kinds of endeavors that capture our interest. My theory: They often relate to things we can see, understand and admire in day to day life. This is probably why more children aspire to be…
marketbeat.com Aspen Aerogels Q2 Earnings Call Highlights Aspen Aerogels NYSE: ASPN said it expects a sharp sequential increase in revenue and adjusted EBITDA in the third quarter, supported by energy-industrial project deliveries, rising General Motors EV…
globenewswire.com Aspen Aerogels, Inc. Reports Second Quarter 2026 Financial Results and Recent Business Highlights Q2 2026 Thermal Barrier revenue of $29.5 million, up 81% quarter-over-quarter Q3 2026 expected revenue range of $65 to $80 million and adjusted EBITDA range of $7 to $15 million European Thermal…
globenewswire.com Aspen Aerogels, Inc. to Present at the 29th Annual Oppenheimer Conference NORTHBOROUGH, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the “Company”), a technology leader in sustainability and electrification solutions, today…
accessnewswire.com ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire /…
globenewswire.com Aspen Aerogels, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call NORTHBOROUGH, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the "Company") today announced that Don Young, President & Chief Executive Officer, and Grant…
